These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 30418275)

  • 1. Bilateral Ulcerative Keratitis Associated With Afatinib Treatment for Non-Small-cell Lung Carcinoma.
    McKelvie J; McLintock C; Elalfy M
    Cornea; 2019 Mar; 38(3):384-385. PubMed ID: 30418275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacist-led patient education and adverse event management in patients with non-small cell lung cancer receiving afatinib in a community-based, real-world clinical setting.
    Khrystolubova N; Shieh M; Patel AJ; Bailey R
    J Oncol Pharm Pract; 2020 Jan; 26(1):13-22. PubMed ID: 30832554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. QT interval prolongation related to afatinib treatment in a patient with metastatic non-small-cell lung cancer.
    Demircan NC; Akın Telli T; Başoğlu Tüylü T; Arıkan R; Kocakaya D; Şahin AA; Ercelep Ö; Dane F; Yumuk PF
    Curr Probl Cancer; 2020 Dec; 44(6):100594. PubMed ID: 32505368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-disciplinary proactive follow-up algorithm for patients with advanced NSCLC receiving afatinib.
    Cheema PK; Thawer A; Leake J; Cheng SY; Khanna S; Charles Victor J
    Support Care Cancer; 2019 Mar; 27(3):1029-1039. PubMed ID: 30116943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammatory changes in actinic keratoses associated with afatinib therapy.
    Kridin K; Wollner M; Bergman R
    Cutis; 2020 Mar; 105(3):E16-E18. PubMed ID: 32352443
    [No Abstract]   [Full Text] [Related]  

  • 6. Ulcerative keratitis in gastrointestinal stromal tumor patients treated with perifosine.
    Shome D; Trent J; Espandar L; Hatef E; Araujo DM; Song CD; Kim SK; Esmaeli B
    Ophthalmology; 2008 Mar; 115(3):483-7. PubMed ID: 18201764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer.
    Engle JA; Kolesar JM
    Am J Health Syst Pharm; 2014 Nov; 71(22):1933-8. PubMed ID: 25349236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.
    Moran T; Palmero R; Provencio M; Insa A; Majem M; Reguart N; Bosch-Barrera J; Isla D; Costa EC; Lee C; Puig M; Kraemer S; Schnell D; Rosell R
    Lung Cancer; 2017 Jun; 108():154-160. PubMed ID: 28625629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, open-label trial evaluating the preventive effect of tetracycline on afatinib induced-skin toxicities in non-small cell lung cancer patients.
    Arrieta O; Vega-González MT; López-Macías D; Martínez-Hernández JN; Bacon-Fonseca L; Macedo-Pérez EO; Ramírez-Tirado LA; Flores-Estrada D; de la Garza-Salazar J
    Lung Cancer; 2015 Jun; 88(3):282-8. PubMed ID: 25882778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.
    Horn L; Gettinger S; Camidge DR; Smit EF; Janjigian YY; Miller VA; Pao W; Freiwald M; Fan J; Wang B; Chand VK; Groen HJM
    Lung Cancer; 2017 Nov; 113():51-58. PubMed ID: 29110849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.
    Soria JC; Felip E; Cobo M; Lu S; Syrigos K; Lee KH; Göker E; Georgoulias V; Li W; Isla D; Guclu SZ; Morabito A; Min YJ; Ardizzoni A; Gadgeel SM; Wang B; Chand VK; Goss GD;
    Lancet Oncol; 2015 Aug; 16(8):897-907. PubMed ID: 26156651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety of afatinib for the treatment of non-small cell lung cancer.
    Barron F; de la Torre-Vallejo M; Luna-Palencia RL; Cardona AF; Arrieta O
    Expert Opin Drug Saf; 2016 Nov; 15(11):1563-1572. PubMed ID: 27633264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Afatinib: An overview of its clinical development in non-small-cell lung cancer and other tumors.
    Giordano P; Manzo A; Montanino A; Costanzo R; Sandomenico C; Piccirillo MC; Daniele G; Normanno N; Carillio G; Rocco G; Bianco R; Perrone F; Morabito A
    Crit Rev Oncol Hematol; 2016 Jan; 97():143-51. PubMed ID: 26318094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bilateral keratitis associated with afatinib therapy.
    Liu YT; Lin CW; Sun CC; Shao SC; Chen NN
    Taiwan J Ophthalmol; 2024; 14(1):121-124. PubMed ID: 38654991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of erosive pustular dermatosis of the scalp following discontinuation of chemotherapy with afatinib.
    Goto K; Nomura T; Kogame T; Irie H; Kaku Y; Dainichi T; Kabashima K
    Eur J Dermatol; 2018 Apr; 28(2):258-259. PubMed ID: 29400287
    [No Abstract]   [Full Text] [Related]  

  • 16. A phase I trial of afatinib and bevacizumab in chemo-naïve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404.
    Ninomiya T; Nogami N; Kozuki T; Harada D; Kubo T; Ohashi K; Kuyama S; Kudo K; Bessho A; Fukamatsu N; Fujimoto N; Aoe K; Shibayama T; Sugimoto K; Takigawa N; Hotta K; Kiura K
    Lung Cancer; 2018 Jan; 115():103-108. PubMed ID: 29290249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma rich in growth factors for the treatment of rapidly progressing refractory corneal melting due to erlotinib in nonsmall cell lung cancer.
    Guarnieri A; Alfonso-Bartolozzi B; Ciufo G; Moreno-Montañés J; Gil-Bazo I
    Medicine (Baltimore); 2017 Jun; 96(22):e7000. PubMed ID: 28562552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib.
    Lee JY; Sun JM; Lim SH; Kim HS; Yoo KH; Jung KS; Song HN; Ku BM; Koh J; Bae YH; Lee SH; Ahn JS; Park K; Ahn MJ
    Clin Cancer Res; 2016 May; 22(9):2139-45. PubMed ID: 26667485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience.
    Kudo K; Hotta K; Bessho A; Nogami N; Kozuki T; Kuyama S; Inoue K; Harita S; Okada T; Gemba K; Fujii M; Takigawa N; Oda N; Tanimoto M; Kiura K
    Cancer Chemother Pharmacol; 2016 May; 77(5):1005-9. PubMed ID: 27029623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing Patient Risk, Benefit, and Outcomes in Drug Development: Insights From Afatinib Clinical Trials Across Diverse Cancer Indications.
    Hunter Hall R; Wright CL; Hughes GK; Peña AM; Ladd C; Gardner B; McIntire R; Ferrell M; Rubenstein J; Tuia J; Haslam A; Prasad V; Vassar M
    Clin Ther; 2024 Jun; 46(6):e107-e113. PubMed ID: 38825553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.